Other languages Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
2.07 ^USD	-2.82%		-11.91%	-47.46%

Apr. 15	Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	CI
Apr. 12	Invivyd Names Jeremy Gowler as Interim CEO	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Invivyd Names Jeremy Gowler as Interim CEO	Apr. 12
Invivyd, Inc. Announces Executive Changes	Apr. 12
Invivyd, Inc. Announces CEO Changes	Apr. 12
Invivyd's Pemgarda Injection to Prevent Covid Available in US -- Shares Rise After Hours	Apr. 04
Invivyd, Inc. Provides Earnings Guidance for the Year 2024	Apr. 04
Invivyd, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Sector Update: Health Care Stocks Rise Tuesday Afternoon	Mar. 26
Invivyd Clears Significant Hurdle After Pemgarda Authorization, Morgan Stanley Says	Mar. 26
Top Premarket Gainers	Mar. 26
Invivyd's Covid Treatment for Immunodeficiency Disorders Gets FDA Nod; Shares Up Before Trading Halt	Mar. 22
Invivyd, Inc. Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial	Mar. 22
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA? (Formerly VYD222) for Pre-exposure Prophylaxis of COVID-19	Mar. 22
Invivyd Submits Request for Emergency Use Authorization to U.S. FDA for VYD222 for the Pre-Exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents	Jan. 03
Invivyd Files Emergency Use Authorization Application for Antibody Candidate Against COVID-19	Jan. 03
Sector Update: Health Care Stocks Rise in Late Afternoon	Dec. 18
Top Midday Gainers	Dec. 18
Invivyd, Inc. Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19	Dec. 18
Invivyd, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19	23-09-11
Invivyd Names William Duke as Finance Chief	23-09-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Invivyd, Inc.

Equities

IVVD

US00534A1025

Other languages

Filters